The emergence of efalizumab, a monoclonal antibody targeting αL, supported the evidence of the relevance between ITGAL and IBD, although it has been withdrawn from the market several years later due to the risk of progressive multifocal leukoencephalopathy [9]. This evidence concerns the gene ITGAL and inflammatory bowel disease.